Hutchison China MediTech Proprietà degli esecutivi
Cos'è Proprietà degli esecutivi di Hutchison China MediTech?
Proprietà degli esecutivi di Hutchison China MediTech Ltd. è 43.90%
Qual è la definizione di Proprietà degli esecutivi?
La proprietà degli esecutivi (Insider Ownership) è calcolata come il numero totale di azioni possedute dagli esecutivi (azionisti che detengono più del 5% della società o un funzionario o direttore della società) diviso per il totale delle Azioni in circolazione.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Proprietà degli esecutivi di aziende nel Health Care settore su LSE rispetto a Hutchison China MediTech
Cosa fa Hutchison China MediTech?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Aziende con proprietà degli esecutivi simili a Hutchison China MediTech
- Techgen Metals Ltd ha Proprietà degli esecutivi di 43.86%
- Dunelm Plc ha Proprietà degli esecutivi di 43.89%
- Membership Collective ha Proprietà degli esecutivi di 43.89%
- CRCAM d'Ille et Vilaine ha Proprietà degli esecutivi di 43.89%
- Boomer ha Proprietà degli esecutivi di 43.89%
- FastForward Innovations ha Proprietà degli esecutivi di 43.90%
- Hutchison China MediTech ha Proprietà degli esecutivi di 43.90%
- Rizhao Port Jurong Co ha Proprietà degli esecutivi di 43.90%
- Rizhao Port Jurong Co ha Proprietà degli esecutivi di 43.90%
- China Assurance Finance ha Proprietà degli esecutivi di 43.91%
- Zoned Properties ha Proprietà degli esecutivi di 43.91%
- Quantum Blockchain Technologies ha Proprietà degli esecutivi di 43.92%
- GMP Capital ha Proprietà degli esecutivi di 43.92%